Recent News

• 02.12.2026 - Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
• 01.05.2026 - Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
• 12.11.2025 - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
• 12.10.2025 - Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
• 12.10.2025 - Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Recent Filings

• 02.10.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.12.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1